GDT-003 (IL-18-FHAB-IL12)
Interleukin 18 (IL-18) has taken center-stage in terms of importance in the immuno-oncology field for eliciting a cytokine-mediated immune response. There has been a lot of effort in the industry toward developing and patenting a modified version of interleukin 18 that doesn’t bind to the IL-18 Binding Protein. IL-18 binding protein binds to IL-18, blocking its activity. GDT 003 IL -18 binding protein resistant (IL-18BPR)) version allows the modified IL-18 variant protein to be fully biologically active in enhancing immunity without binding to the IL-18 binding protein.
Related Programs
Phase 1 | Solid Tumors
GDT-001 (IL12-FHAB)
A IL-12 immunotherapy candidate designed to be best-in-class to turn 'cold' tumors 'hot’ while avoiding systemic immune-activation toxic effects. Currently in Phase 1 for advanced solid tumors and in combination with trabectedin (Yondelis®) for Soft-Tissue Sarcomas .Currently seeking partnership to move this forward into Phase 1B/IIA.
IND ready | Bladder Cancer and Solid Tumors
GDT-002 (IL12-FHAB-IL15)
A first-in-class IL-12+IL-15 immunotherapy candidate delivering dual cytokine action directly to the tumor microenvironment.
Interested in GDT-003?
Guidant BioTherapeutics is actively engaging with potential partners and licensees interested in leveraging the strength of our proprietary FHAB technology platform.